Indefinite Delivery Contract SPE2DR25D9966

The federal contract IDV award SPE2DR25D9966 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities worldwide.

This IDC is part of the broader DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to the Department of Defense, United States Coast Guard, and other designated government customers. The unrestricted, fully competitive solicitation, expected to be issued in March 2024, has an estimated total value of $30.3 billion and will award at least three different contractors across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet (CONUS/OCONUS) regions on a lowest price technically acceptable basis.